Recent Uptick Might Appease Editas Medicine, Inc. (NASDAQ:EDIT) Institutional Owners After Losing 35% Over the Past Year
Express News | Editas Medicine Inc : RBC Cuts Target Price to $8 From $11
Editas Medicine (NASDAQ:EDIT) Investors Are Sitting on a Loss of 90% If They Invested Three Years Ago
Synthetic Immunology Market Report 2024 With Profiles of ADC Therapeutics, BioNTech, Camena Bioscience, CRISPR Therapeutics, Editas Medicine, Sherlock Biosciences, Synlogic Therapeutics & Synthego
Is Editas Medicine, Inc. (EDIT) One of the Best Biotech Penny Stocks to Buy Now?
What Makes Editas Medicine, Inc. (EDIT) One of the Best Small-Cap Stocks With Highest Upside Potential?
SeqWell Launches Loaded-transposase Portfolio to Support Expanding Use of NGS-based Gene Editing Analysis Methods
Shareholders in Editas Medicine (NASDAQ:EDIT) Have Lost 87%, as Stock Drops 17% This Past Week
Unveiling 5 Analyst Insights On Editas Medicine
Editas Medicine Is Maintained at Perform by Oppenheimer
Oppenheimer Maintains Editas Medicine(EDIT.US) With Hold Rating, Maintains Target Price $12
BofA Securities Maintains Editas Medicine(EDIT.US) With Hold Rating, Cuts Target Price to $13
Editas Medicine Says Its Gene Editing Potential Treatment for Sickle-Cell Disease Found Well-Tolerated in Phase 1/2 Trial
Editas Medicine Reveals Updated Safety And Efficacy Results From The RUBY Trial Of Reni-Cel In 18 Sickle Cell Patients At EHA
Express News | Editas Medicine Inc - All Patients Treated in Edithal Trial Maintained Hemoglobin Levels Above Transfusion Threshold and Are Transfusion-Free
Express News | Editas Medicine Announces New Safety and Efficacy Data From the Edithal Trial of Reni-Cel in 7 Patients With Transfusion-Dependent Beta Thalassemia, Presented at the European Hematology Association (Eha) Annual Congress
Form 144 | Editas Medicine(EDIT.US) Officer Proposes to Sell 127.68K in Common Stocks
SEC FILLINGS DISCLOSED/ May 31, $Editas Medicine(EDIT.US)$ Officer O'Neill Gilmore Neil intends to sell 24,000 shares of its common stock on Jun 3, with a total market value of approximately $127.68K.
The Analyst Verdict: Editas Medicine In The Eyes Of 4 Experts
Editas Medicine Is Maintained at In-Line by Evercore ISI Group
Editas Medicine Analyst Ratings